Verona Pharma(VRNA) - 2024 Q3 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Title of each classTrading Symbol(s) Name of each exchange on which registered Ordinary shares, nominal value £0.05 per share* VRNA The Nasdaq Stock Market LLC (Nasdaq Global Market) Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ For the quarterly period ended Se ...